13 Chapter 13: Contraception

Learning Objectives

  • Analyze psychosocial and cultural factors impacting contraception use.
  • Discuss best practices to promote equity within healthcare systems and regarding access to resources.
  • Demonstrate understanding of contraception by describing: ways in which sexual partners can share responsibility for it; how various methods work along with the advantages and disadvantages of each; and the effectiveness of hormone-based contraceptives, barrier methods, intrauterine devices, emergency contraception, cycle-based methods, and sterilization.
  • Describe the current U.S. political and legal landscape as it relates to contraceptive access, including the implications of Dobbs v. Jackson Women’s Health Organization and ongoing insurance coverage challenges.
  • Identify digital reproductive health tools and evaluate the data privacy considerations associated with their use in the post-Dobbs context.

Introduction

One could argue that as long as humankind has had an awareness of how conception occurs, there have been efforts to prevent it. The history of contraception – the deliberate use of techniques to prevent pregnancy or sexually transmitted infections – is long, varied, and deeply human. In the United States, contraception is fraught with complexity. On the one hand, there have been remarkable innovations that have expanded reproductive autonomy.  On the other hand, there’s a sordid history of mistreatment and forced sterilization of marginalized people, a history that still echoes to this day.

This chapter attempts to hold both of those truths at once. We will trace the historical arc of contraception from ancient civilizations through the 20th-century pill revolution, describe the various types of contraceptive methods available today and how they work, examine the persistent inequities in who has access to contraceptive care and who has been harmed by it, and address the rapidly shifting political and legal landscape that is reshaping contraceptive access right now. We will also look ahead to emerging innovations and to the role of digital technology in reproductive health. There is a lot of ground to cover — and all of it matters.

A note on scope: while contraception is a global issue — with significant variation in access, legality, cultural, and healthcare access across countries — this chapter focuses primarily on the United States. Where global context appears, it is to illustrate the reach of U.S. policy decisions or to situate American practices within a broader frame. As you read, we encourage you to consider how the dynamics described here might look different elsewhere in the world.

Early History of Contraception – An Overview

As the old adage goes, “Necessity is the mother of invention” and, indeed, contraception is no exception to this rule. Among the earliest recorded accounts of contraception is a story from ancient Greek mythology: Pasiphae, the wife of King Minos of Crete, reportedly inserted a goat bladder into her vagina before having sex with her husband, fearing that his semen contained “serpents and scorpions” (Khan, Mukhtar, Dickinson, & Sriprasad, 2013). While Pasiphae herself is a mythological figure, the account reflects real historical practices — the earliest documented evidence of contraceptive use comes from ancient Egypt, including the Kahun Gynecological Papyrus (~1825 BCE), which describes pessaries and other methods used to prevent conception. There’s also evidence in support of Ancient Greeks and Egyptians using a diaphragm made out of crocodile dung, honey, and sodium carbonate to prevent pregnancy (Lehmiller, 2019; Tye, 2020). The Ancient Egyptians were one of the first civilizations to use barrier methods in the form of sheaths, often made out of linen while Chinese civilizations utilized silk paper applied with oil. Early Japanese civilization used a shell to cover the glans of the penis and the Djukas tribe of New Guinea are on record for using an internal condom made out of a specific plant, which prevented conception (Khan, et al, 2013; Lehmiller, 2019).

By the Renaissance, contraception was regarded as being both a safeguard from disease, as well as unintended pregnancy with condoms emerging with greater use (most were made from linen or animal intestines or bladders of goats, sheep, cattle, or fish). From Ancient cultures to the Renaissance and forward, the wisdom of herbs, teas and tinctures were also passed down from woman to woman. The popular ballad, “Scarborough Fair” was thought to hold the secret to avoiding pregnancy through the use of parsley, sage, rosemary and thyme and pennyroyal tea was commonly used as an abortifacient (Bilger, 1998). By the middle to late 19th century condoms and investigations to hormonal contraceptives were underway, paving the way for 20th and 21st century innovation and use.

Types of Contraceptives

Behavioral Methods

Before diving into the modern range of methods, let’s first consider the scope of contraceptive use. In the United States, there were approximately 75.9 million women (defined by the Guttmacher Institute, 2024) as individuals who may have the ability to become pregnant) of reproductive age (15–49). Out of that number, 51.9 million were estimated to have a self-defined need for contraceptive services and supplies (Guttmacher Institute, 2024). Among sexually active people not seeking pregnancy, 88% used a contraceptive method — a proportion that has remained relatively stable since 2002, though use is somewhat lower among those aged 15–24 (83%) compared to those aged 25–34 (91%; Guttmacher Institute, 2021).

In early folklore, behavioral techniques to prevent pregnancy were often based on superstition or storytelling. For example, women were often instructed to jump up and down to get rid of the semen in their vagina or to sneeze or cough heartily (Lehmiller, 2019). Unsurprisingly, these methods weren’t very effective. Perhaps the most successful form of contraception is abstinence and, indeed, its virtue has been touted for generations. Although, theoretically, abstinence emerges as the most cost effective and reliable form of contraception, it’s not always the most attainable or realistic. In cases where sexual intercourse is likely to occur but where accessibility to contraception is limited or religiosity forbids certain forms of protection, behavioral methods are often employed. These methods are typically designed to reduce the chance of conception versus STI prevention.

One of the most commonly known behavioral methods of contraception is the withdrawal method – in which the penis is withdrawn from the vagina before ejaculating. Unfortunately, this method is the least effective form of birth control: research indicates that nearly a quarter of women (22%) using this method will become pregnant within a year (Guttmacher, 2021; Tye, 2020). Sperm can be present in pre-ejaculate, contact with the labia or clitoris can result in conception, and timing is not always accurate.

Timed abstinence, or the rhythm method, is another common behavioral strategy. This approach utilizes reliance of menstrual cycle tracking with avoidance of sex during ovulation. Again, its efficacy is compromised when there are variation of implementation. Additionally, even with more technological advances in tracking menstrual cycles (period apps, ease of temperature recording, etc), physiological variations (like irregular periods) can reduce this method’s efficacy.

Finally, another behavioral contraceptive method that is very specific to certain situations involves breastfeeding. Known formally as the Lactational Amenorrhea Method (LAM), this approach relies on breastfeeding’s natural suppression of ovulation. The 2% failure rate cited for LAM applies only when all three of the following conditions are met: the person is exclusively or nearly exclusively breastfeeding (typically 6–8 times per day, including at night), menstrual periods have not yet returned (amenorrhea), and the infant is less than six months old. When all three conditions are satisfied, LAM is a recognized and reasonably reliable contraceptive method. However, if any one condition is not met — for example, if supplemental feeding has been introduced or menstruation has resumed — the method’s efficacy drops significantly and additional contraception is recommended. There are some data suggesting protection may extend to nine months postpartum under ideal conditions, though six months is the more widely supported threshold (Tye, 2020).

One behavioral method that isn’t often discussed, in part because of continued taboos about the behavior, is sex during menstruation. It’s actually more common than one may realize (some like the additional lubrication and/or the spike in arousal), while others may be averse to the idea. To be clear, sex during menstruation is completely safe (do watch for STI prevention, however). Importantly, sex on your period in NOT a contraceptive strategy. Indeed, because some sperm can live up to a week and because some menstrual cycles are irregular, pregnancy can still occur so additional contraception may be needed (Tye, 2020).

A brief word on technology: many people now use cycle-tracking apps as part of behavioral contraceptive approaches. While these tools can be genuinely useful, it is important to be aware that in the current legal and political landscape, the data collected by these apps may not be protected in the same way as medical records. We return to this topic in the section on digital reproductive health tools later in this chapter.

Barrier Methods

Earlier we discussed how evidence of barrier methods, be it a condom or a diaphragm, appeared in ancient civilizations. By the time we reach mid-late 19th century, significant advances were made, and in 1860, condoms were produced on a large scale. In part, this was because the vulcanized rubber introduced by Charles Goodyear (yep- the tire guy) changed the ability to mass produce condoms (versus relying on animal products). Originally, rubber condoms were made to scale and were reusable (Khan, et al, 2013). Unfortunately, U.S. Postal Inspector and secretary of the New York Society for the Suppression of Vice, Anthony Comstock, lobbied for the prohibition of any type of advertising or print materials involving contraception. In 1873, the Comstock Act was passed, making it a federal offense to disseminate contraceptive information and, ultimately, a series of “Comstock Laws” were implemented nationwide, resulting in the criminalization of contraceptive use (Bailey, 2010).

In 1920, the invention of latex reshaped condom production. During World Wars I and II, rates of STIs among American soldiers skyrocketed and distribution of condoms finally appeared on scene during WW II. Post-war attitudes toward contraception started to shift in the late 1940s (Khan, et al, 2013). Still, it wasn’t until 1965, in the Supreme Court decision on Griswold vs. Connecticut that attitudes and accessibility of contraception takes a dramatic shift toward legality and acceptance (Bailey, 2010).

The most commonly used barrier method in the United States is the male condom (Copen, 2017; Daniels & Abma, 2018). According to the Guttmacher Institute (2021), 5.7 million women rely on male condoms for their contraception needs, making it the most common among 15 to 19 year olds, those born outside of the U.S. and uninsured college graduates (and a few others). While condom use is the most effective in the prevention of STIs, its use in pregnancy prevention yields more variable results.

With perfect use, condoms have a 98% efficacy rate in preventing pregnancy. However, that number declines to 82% when human error is factored in (Lehmiller, 2019). The most common mistakes with condom use is not using them correctly, not using them each time intercourse occurs, and breakage (Tye, 2020). Other issues include failing to withdraw promptly after ejaculation, using latex-incompatible lubricant (remember not to mix oil-based lube with latex), and reusing condoms (Lehmiller, 2019).

Did you know that almost all 50 states and Washington DC have free condom programs via state and local health department programs? Many states will send you free condoms by mail – making access much easier. Check your state health department’s website or search “[your state] free condoms” to find local options.

Other barrier methods include the internal condom (sometimes called the female condom) and cervical barriers, such as the diaphragm and cervical cap. The internal condom is typically made out of nitrile (versus latex) and is a hollow closed cylinder with an outer and an inner ring. The inner ring fits close to the cervix, while the out ring remains outside the labia (some report enjoying the extra clitoral stimulation). If the inner ring is removed, it can also be used for anal sex. Available widely throughout Europe, the internal condom can also be obtained in the US at pharmacies, online, or through some reproductive health clinics/outlets (Lehmiller, 2019; Tye, 2020). When it’s used as a female condom and barring any errors, the internal condom is believed to be as effective as the male condom in preventing pregnancy and STIs. Unfortunately, the internal condom is a bit more complicated, resulting in less efficacy (Tye, 2020).

The diaphragm and cervical cap are both designed to be inserted into the vagina before sexual intercourse (and, historically, with the addition of spermicide). Once quite popular in the United States, this is one of the least common forms of contraception today. Still, it is cost-effective (a diaphragm or cervical cap can last up to a year) but it does require fitting it to your particular cervix and a comfort in insertion before sex. Additionally, they need to be left in the body six hours post intercourse to ensure protection. When used without error, the effectiveness of preventing pregnancy is up to 96%, though 88% effective with typical use (Lehmiller, 2019). For more information comparing and contrasting barrier methods of contraception, check out the Planned Parenthood website.

Hormonal Contraception

Historical Notes

The history of hormonal contraception is both groundbreaking and morally complicated — and it is worth sitting with both of those things. Despite the range of contraceptive practices used for centuries, the Comstock Act of 1873 dramatically restricted access to and knowledge about contraception throughout the United States. One of the most formidable opponents of Comstock laws was Margaret H. Sanger (1879–1966). A suffragette and advocate for social reform, Sanger argued that the right to control one’s own body was a fundamental human right, and that every person should be able to decide when and whether to have a child. Working as a nurse among impoverished families on New York’s Lower East Side, she witnessed firsthand the devastation of unintended pregnancies and unsafe abortions. Following the death of one patient from a self-induced abortion, she left nursing to devote herself fully to birth control advocacy (Nunez-Eddy & Malladi, 2016; Planned Parenthood, 2016; Tye, 2020).

Sanger was repeatedly targeted by law enforcement for her work. She was held in contempt for violating the Comstock Act in 1912, and she continued to face prosecution throughout her career. She ultimately founded the American Birth Control League in 1921 — which later became the Planned Parenthood Federation of America — and her advocacy contributed substantially to the eventual reversal of Comstock laws and the development of the birth control pill (Nunez-Eddy & Malladi, 2016; Tye, 2020).

As pioneering as Sanger’s work was, she is also a figure who held eugenicist views that cannot and should not be minimized. Eugenics — the notion of selective reproduction to promote supposedly “favorable” traits — shaped parts of her thinking and the broader birth control movement of her era. The birth control pill emerged in part from concerns about population control rooted in deeply racialized assumptions about whose reproduction was desirable. Sanger’s own statements on forced sterilization are ambiguous, and historians continue to debate the extend of her role  (Nunez-Eddy & Malladi, 2016). Still the presence of ableist and racist ideology in her work is important to acknowledge rather than overlook. A thorough reading of any influential figure demands exactly this kind of critical engagement — not to arrive at a final verdict of hero or villain, but to understand how even transformative work can carry harmful assumptions, and why naming those assumptions matters for the people most affected by them. For Planned Parenthood’s own reckoning with Sanger’s legacy, see their published statement at plannedparenthood.org.

Magazine layout featuring Gandhi on the left and Sanger on the right, with their opinion of birth control in marriage.
An op-ed from Liberty Magazine, circa 1939 (image taken by Goerling, 2026).

Because of Sanger’s advocacy and the efforts of many others, the first commercial birth control pill — Enovid — was introduced to the public in 1960 (Bailey, 2010; Buttar & Seward, 2009). Marketed specifically for married couples, it remained inaccessible in some states until the Supreme Court’s 1965 decision in Griswold v. Connecticut, which affirmed the right of married couples to contraceptive privacy (Bailey, 2010; Tye, 2020). A second landmark case, Eisenstadt v. Baird (1972), extended those protections to unmarried people (Tye, 2020). The availability of reliable contraception, combined with broader cultural shifts, was instrumental in advancing women’s rights in profound ways (Bailey, 2010; Tye, 2020). That same Comstock Act, once used to suppress contraceptive information, has re-emerged in recent years as a legal tool in efforts to restrict reproductive health access — a thread we return to in the section on the contemporary political landscape.

Oral Contraceptives

The birth control pill is the second most common form of contraception globally and the most commonly prescribed contraceptive in the United States (Cooper & Mahdy, 2020). Approximately four out of five sexually active people with uteruses have used the pill at some point, though numbers are shifting as other hormonal options gain popularity (Guttmacher Institute, 2021).

There are three main types of oral contraceptives: combined estrogen-progesterone pills (the most commonly prescribed), progestogen-only pills, and continuous or extended-use pills (Cooper & Mahdy, 2020; Lehmiller, 2019; Tye, 2020). When used perfectly — taken at the same time every day with no deviation — oral contraceptives are 98–99% effective at preventing pregnancy. With typical use, accounting for human error, the failure rate rises to approximately 9% (Cooper & Mahdy, 2020). For more on the types of oral contraceptive options, please check out the CDC and Planned Parenthood.

Myths, Misinformation, and What the Research Actually Shows

One of the most important things a health educator or healthcare provider can do is help people distinguish between real side effects, overstated risks, and outright myths — particularly as social media has become a significant source of health information. A growing body of research addresses common misconceptions about hormonal contraception (Black et al., 2025), and what follows is a brief, evidence-based review.

Fertility after stopping the pill: Many people worry that hormonal contraception will impair their ability to conceive in the future. Research shows this concern is largely unfounded. Pregnancy rates within one year of discontinuing contraception are comparable to those of people who never used hormonal methods (Black et al., 2025). One recent review found a pregnancy rate of 83.1% within 12 months of stopping contraception. Anti-Müllerian hormone (AMH) levels — a marker of ovarian reserve — may be temporarily lower during hormonal contraceptive use, but this effect reverses after discontinuation (Black et al., 2025).

Cancer risk: This is a nuanced area that deserves honest treatment rather than either dismissal or alarm. There is a small, real association between current hormonal contraceptive use and breast cancer risk, with a pooled odds ratio of approximately 1.33 in recent meta-analyses (Black et al., 2025). This is a modest elevation, and it should be weighed against well-established protective effects: hormonal contraceptive use is associated with significantly reduced risks of both ovarian cancer (up to 42% reduction for current users) and endometrial cancer (approximately 50% risk reduction after 10–15 years of use, with protection persisting for over 30 years after discontinuation; Black et al., 2025). These are meaningful benefits that often go unmentioned in public discussions of hormonal contraception.

Depression and mood: The relationship between hormonal contraception and mood is one of the most actively debated topics in reproductive health, and one where social media frequently overstates the evidence. Systematic reviews and meta-analyses of randomized controlled trials have found no consistent association between hormonal contraceptive use and clinical depression compared to placebo groups (Black et al., 2025). Some individuals — particularly adolescents — may be more sensitive to hormonal changes, and this warrants individualized conversation. However, the narrative that the pill invariably causes depression is not supported by high-quality evidence. Other reported effects on mood, sexual desire, emotion recognition, and stress response have been observed in smaller studies and merit continued investigation (Cooper & Mahdy, 2020; Lewis et al., 2019; Pahnke et al., 2019).

Weight gain: Research on this concern is similarly mixed. Well-designed studies generally do not support a significant causal link between combined oral contraceptives and meaningful weight gain, though individual variation exists and some progestogen-only injectables have been associated with modest weight changes (Black et al., 2025).

The “unnatural hormones” concern: Some people are reluctant to use hormonal contraception because the idea of introducing synthetic hormones feels uncomfortable or unnatural. This is a legitimate value that deserves non-dismissive engagement. Healthcare providers can acknowledge this concern while also sharing that the hormones in modern low-dose contraceptives function at physiological levels and have been studied for over 60 years. Ultimately, the right contraceptive choice is one that aligns with a person’s own values, health history, and life circumstances.

Other Hormonal Contraceptive Options

Beyond the pill, several hormonal contraceptive methods use similar hormonal compositions delivered through different routes. The injectable method (e.g., Depo-Provera) is administered once every three months. The transdermal patch (e.g., Ortho Evra) is worn on the skin and changed monthly. The vaginal ring (e.g., NuvaRing) is inserted vaginally and also replaced monthly (Lehmiller, 2019; Planned Parenthood, 2020; Tye, 2020). Each of these offers a more hands-off approach than daily pill-taking, which can improve adherence for some users.

Long-Acting Reversible Contraceptives (LARCs)

Long-acting reversible contraceptives represent one of the most significant developments in modern contraceptive care. LARCs include the subdermal implant and intrauterine devices (IUDs), both of which are set-and-forget options that can be removed at any time with fertility returning quickly afterward.

The subdermal implant (e.g., Nexplanon) is a small, flexible rod inserted under the skin of the upper arm. It releases a low, steady dose of progestogen, lasts up to five years, and has an efficacy rate of over 99% — making it one of the most effective contraceptive methods available (Lehmiller, 2019).

IUDs are small, T-shaped devices inserted into the uterus by a healthcare provider. There are two main types. Hormonal IUDs (e.g., Mirena, Kyleena, Liletta, Skyla) release progestogen locally and are approved for three to eight or more years depending on the device. The copper IUD (ParaGard) is hormone-free, approved for up to 10 years, and works by creating an environment that is toxic to sperm. Both types are over 99% effective at preventing pregnancy (Lehmiller, 2019). Notably, the copper IUD is also the most effective form of emergency contraception available, working when inserted within five days of unprotected intercourse. Recent research suggests that the 52 mg hormonal IUD may offer comparable emergency contraceptive efficacy during the same window (Durante et al., 2023).

In a long-overdue update to clinical guidance, the CDC’s 2024 U.S. Selected Practice Recommendations for Contraceptive Use finally addressed pain management during IUD placement. Notable updates to the 2024 guidelines included updated recommendations for provision of medications for IUD placement. This update is significant because concerns about procedural pain have historically been a barrier to IUD uptake — for both patients and providers (CDC, 2024).

The use of LARCs has increased substantially in recent decades, including among adolescents (Durante et al., 2023). Still, LARC use is highest among people aged 25–34 (Daniels & Abma, 2018; Guttmacher Institute, 2021), and the proportion using injectable methods increased from 5% in 1995 to 23% in 2006–2010 (Guttmacher Institute, 2021).

Important Considerations: Equity in Contraceptive Access

Access to hormonal contraception remains deeply unequal in the United States, with the burdens of limited access falling most heavily on marginalized communities — including people of color, those living in poverty, immigrants, people with disabilities, and gender-diverse individuals. Among sexually active people not seeking pregnancy, contraceptive use is lower among those without insurance (81%) compared to those with private insurance (90%), and lower among people with incomes below the federal poverty level (86%) compared to those at 300% or more of the poverty level (91%; Guttmacher Institute, 2021). Although unintended pregnancy rates have declined across all racial groups (from 51% in 2008 to 45% in 2011), racial gaps have persisted even when controlling for income (Jackson et al., 2017; Rocca & Harper, 2012; Wright, 2020).

Many of the disparities rooted in structural racism, which impacts minority women also impact women with disabilities. Among American women who fall within the reproductive age range, 12-18% percent have a disability related to mobility, vision, hearing, cognitive functioning and/or independent living. Unfortunately, women with disabilities are often subjected to healthcare bias and deemed asexual, which is not rooted in the experience of many these women. Multiple studies have shown that disabled women are less likely to receive gynecological exams and/or contraceptive counseling (Horner-Johnson et al., 2021).

An additional area of consideration for contraceptive counseling, access, and patient-centered care is in the responsiveness to transgender and gender-diverse people. With approximately one in 200 adults identifying as transgender, this domain of care is essential to update. In one study of 26 transgender men, half were at risk for unintended pregnancy (Cipres et al., 2017). Importantly, evidenced-based care, which includes a patient-centered approach, is of paramount importance since each transmasculine or gender diverse patient has their own unique set of goals and concerns in terms of their reproductive health (Bonnington et al., 2020).

In the examination of intersectional identities and contraceptive use, a few important findings come to light. First – there is consistent evidence that Black, Latina, Native American, Pan-Asian, disabled, gender diverse and poor women experience barriers to contraceptive access, have higher rates of contraceptive failure, and increased risks of adverse outcomes (Horner-Johnson, et al, 2021; Jackson, Wang, & Morse, 2017; Wright, 2020).

Secondly, practitioners of all types should acknowledge the history of inequity and structural racism, particularly as it still pertains to contraceptive access to this day.

Finally, there is an increased need to address women’s intersectional identities in response to their contraceptive needs, taking into account historical injustices and current, systemic inequities. As Kelsey Wright argues, “…contraceptive services should be offered to women in ways that ensure access to reproductive justice without obscuring the need for social changes in the institutions that create disadvantages and shape contraceptive use itself” (Wright, 2020, p. 1).

Male and Partner-Based Contraception: Shared Responsibility

Contraception has historically been understood as a woman’s responsibility. That framing is worth questioning. The burden of managing contraception — with its costs, side effects, time demands, and healthcare navigation — falls almost entirely on people with uteruses. A growing body of research and a growing number of people are pushing back on this imbalance, and the science of male contraception has advanced considerably in recent years.

Vasectomy

Male sterilization, or vasectomy, involves sealing or severing the vas deferens so that sperm can no longer be present in ejaculate. Sperm comprises only a small fraction of seminal fluid, so ejaculate volume is essentially unchanged. Vasectomy is considered low-risk, 99% effective, and does not impair sexual functioning (Lehmiller, 2019; Tye, 2020). It is worth noting that demand for vasectomy increased substantially in the years following the 2022 Dobbs decision (Weisman et al., 2025), suggesting that some people with testes are actively seeking to share contraceptive responsibility in the face of restricted options for their partners.

Hormonal Male Contraception in Development

Research on hormonal male contraception has been ongoing since the 1970s (Bania et al., 2025). The basic principle is straightforward: exogenous androgens can suppress gonadotropin secretion through the hypothalamic-pituitary-gonadal axis, reducing sperm production to levels insufficient for fertilization. The challenge has been developing compounds that do this effectively with manageable side effects and convenient administration.

The most promising current candidate is NES/T, a transdermal gel combining nestorone (a progestogen) and testosterone. In clinical trials, NES/T reduced sperm concentrations below the effective contraceptive threshold in 88–89% of participants, with no serious adverse events reported (Bania et al., 2025; Anderson et al., 2025). Oral candidates including dimethandrolone undecanoate (DMAU) and 11β-MNTDC are also in trials, offering the convenience of a daily pill. Side effects across these compounds are not unlike those associated with female hormonal contraception: acne, mild mood changes, shifts in libido, and modest weight changes — though reported rates are generally low (Bania et al., 2025).

Public interest in male hormonal contraception is substantial. A 2022 survey found that 75% of men in the United States and Canada are interested in using hormonal contraception (Bania et al., 2025). Between 43–94% of women surveyed expressed willingness to use potential male contraceptives as a couple, depending on the specific method (Bania et al., 2025). It is worth acknowledging an uncomfortable double standard in contraceptive development: the threshold for acceptable side effects in male contraceptive trials has historically been set higher than it was for female methods developed decades earlier — a reflection of who has borne the burden and who has set the research agenda (Bania et al., 2025).

Non-Hormonal Male Approaches in Development

Beyond hormonal methods, researchers are exploring targeted non-hormonal approaches. Soluble adenylyl cyclase (sAC) inhibitors work by blocking a molecule essential for sperm motility. In animal studies, a single dose of an sAC inhibitor rendered male mice temporarily infertile, with fertility fully restored within 24 hours (Anderson et al., 2025). YCT529, a retinoic acid receptor alpha (RAR-α) antagonist, has shown promising results in early human trials. These on-demand approaches are particularly appealing because they would not require daily dosing or long-term hormonal exposure.

Emergency Contraception

Emergency contraception (EC) is not a regular contraceptive method — it is used after unprotected sex or contraceptive failure to reduce the risk of pregnancy. It is not an abortifacient: EC works primarily by delaying or preventing ovulation, and it cannot terminate an established pregnancy (American College of Obstetricians and Gynecologists [ACOG], 2025).

There are three main types of emergency contraception available in the United States:

Levonorgestrel EC (Plan B and generics). The most widely available EC option, levonorgestrel pills (e.g., Plan B One-Step and its generic equivalents) are available over the counter without a prescription. They are most effective when taken as soon as possible after unprotected sex and are approved for use within 72 hours, though they retain some effectiveness up to 120 hours (five days). Efficacy declines with time: effectiveness is approximately 95% within 24 hours, dropping to around 58% between 48–72 hours. Levonorgestrel EC is less effective in people with a higher body weight (Lehmiller, 2019; Tye, 2020).

Ulipristal acetate (ella). Available by prescription in the United States, ulipristal acetate maintains more consistent effectiveness across the full 120-hour window compared to levonorgestrel, making it the preferred pill-based option when more than 72 hours have passed since unprotected sex. Research also suggests it is more effective across a wider range of body weights (Lehmiller, 2019).

The copper IUD (ParaGard). As noted in the LARC section above, the copper IUD is the most effective form of emergency contraception, with a failure rate of less than 1% when inserted within five days of unprotected sex. It has the additional advantage of providing ongoing contraception for up to 10 years after placement (Lehmiller, 2019). Recent research suggests the 52 mg hormonal IUD may offer comparable emergency contraceptive efficacy within the same window (Durante et al., 2023).

It is worth noting that EC has become a more prominent part of contraceptive planning in the post-Dobbs context. A 2024 national survey found that a meaningful proportion of reproductive-age people reported keeping emergency contraception on hand in response to the shifting legal landscape (Weisman et al., 2025). The political debate over whether EC functions as an abortifacient — a claim rejected by mainstream medical science and ACOG — is discussed further in the section on the contemporary political and legal landscape.

Sterilization

The final form of contraception to discuss is sterilization, an irreversible form of birth control that is the most, overall, commonly used in the United States and globally (Daniels & Abma, 2018; Guttmacher Institute, 2021). Typically applied to folks on the older end of the reproductive spectrum (ages 35-44) who have already had children, there are two kinds of sterilization to know. Female sterilization, or tubal ligation (tubectomy), is the process of clamping or severing the fallopian tubes so that any eggs released cannot meet sperm for fertilization. Male sterilization (vasectomy) was discussed in the preceding section. Both procedures are considered low-risk and 99% effective, and neither impairs sexual functioning (Lehmiller, 2019; Tye, 2020).

Demand for sterilization has shifted in recent years. Rates of both tubal ligation and vasectomy among adults aged 18–30 increased significantly following the Dobbs decision, suggesting that some people are seeking permanent contraception in response to the erosion of other reproductive health options (Weisman et al., 2025).

Forced Sterilization as a Form of Racism: A History We Must Not Forget

Although sterilization is a sound and viable option for many people in terms of contraception, there are some inequities in terms of who receives sterilization, which is born from a sordid history of coerced and forced sterilization. Summarized in Guttmacher Institute (2021) report, sterilization “is most common among blacks and Hispanics, women aged 35 or older, ever-married women, women with two or more children, women living below 150% of the federal poverty level, women with less than a college education, women living outside of a metropolitan area, and those with public or no health insurance” (p. 2). When considering issues of contraceptive decision making with minority and underrepresented women, listening and understanding their potential distrust in medical systems is essential (Horner-Johnson et al., 2021; Jackson, Wang, & Morse, 2017; Wright, 2020).

In the mid-19th century, the eugenics movement, spearheaded by Sir Francis Galton, advocated for the advancement of promising heritability. By the late 1800s this campaign endorsed the elimination of hereditary “blights” such as non-whiteness, ‘feeble-mindedness,’ physical impairments or criminality. The United States was the first nation to enact laws of forced sterilization and in 1907, the state of Indiana allowed and/or required the sterilization of criminals, the intellectually disabled (ID) and institutionalized people with other mental and physical impairments. Other states soon followed and in 1927, the case Buck v. Bell was decided by the US Supreme Court (SCOTUS), which ruled 8–1 to uphold Virginia’s forced sterilization law, enshrining the constitutionality of forced sterilization in federal law. The case had been brought by Virginia woman Carrie Buck, who had been forcibly sterilized and deemed unfit due to her so-called ‘feeble-mindedness.’ Justice Oliver Wendell Holmes, writing for the majority, infamously declared: “three generations of imbeciles are enough.” The SCOTUS ruling all but ensured the continuation of negative eugenics throughout the country for decades to come — and Buck v. Bell has never been formally overturned (Amy & Rowlands, 2018; Asbury, 2015; Stern, 2005).

After World War II, global outrage at Nazi atrocities — atrocities that were in part modeled on American eugenics programs — diminished public enthusiasm for explicit eugenics. But the practice did not end; it simply changed its framing. By mid-century, tens of thousands of forced sterilizations had occurred in at least 32 states, with a third of those in California alone, disproportionately targeting poor Black and Latina women (Stern, 2005). Virginia and North Carolina maintained alarmingly high rates of sterilization of poor Black women (Amy & Rowlands, 2018; Asbury, 2015).

By the 1960s, sterilization was increasingly reframed as “voluntary” family planning, but that label obscured the reality: many people were sterilized without complete information, were required to consent to sterilization to continue receiving federal benefits, or were simply lied to. A devastating example: by the late 1960s, 35% of all Puerto Rican women aged 20–49 had been sterilized (Krase, 2014). In 1973, the Relf sisters — ages 12 and 14 — were forcibly sterilized in Alabama. Their mother, who signed the consent form believing the procedure was reversible, had been threatened with the loss of public benefits if she refused. A federal court ruled in their favor, finding that “an indefinite number of poor people have been improperly coerced into accepting a sterilization operation under the threat that variously supported welfare benefits would be withdrawn unless they submitted” (as cited in Stern, 2005, p. 7).

During the 1960s and 70s, approximately 40% of Native American women alive at the time — between 60,000 and 70,000 people, along with 10% of Native American men — underwent sterilization (Amy & Rowlands, 2018; Blakemore, 2016). In California, a federal lawsuit, Madrigal v. Quilligan, was brought by Mexican American women who had been coerced into consenting to sterilization while in the midst of labor, often told they would not receive pain medication unless they signed. Though they did not prevail in court, the case catalyzed important policy changes including the requirement for bilingual consent forms (Stern, 2005).

By 1983, 43% of people sterilized in federally funded family planning programs were Black, at a time when Black people comprised only 12% of the general population (Asbury, 2015). Coercive contraceptive practices continued in subtler forms through the 1990s, when access to experimental contraceptive options like Norplant was sometimes tied to receipt of public benefits for low-income women. As Asbury (2015) writes, targeting coercive contraception at poor Black women “is antithetical to promoting their reproductive freedom and should be understood as a modern manifestation of historical eugenic efforts seeking to discourage reproduction by marginalized populations” (p. 13).

And this is not merely history. In September 2020, whistleblower nurse Dawn Wooten revealed that women detained at the Irwin County Detention Center in Georgia were being transferred to a physician who performed hysterectomies and other gynecological procedures without proper informed consent (Manian, 2020). The pattern is old. The practice is not.

Is it any wonder, then, that many people from marginalized communities approach contraceptive counseling with caution — or with outright distrust? Building trust in these contexts is not a communication technique; it is a matter of historical accountability. Providers who understand this history are better equipped to offer care that is genuinely patient-centered.

The Contemporary Political and Legal Landscape

If the history of contraception in the United States teaches us anything, it is that the legal status of reproductive healthcare is never simply a given. It must be actively maintained — and it can be actively dismantled. The years since 2022 have made that lesson urgent again.

Dobbs v. Jackson Women’s Health Organization and the Threat to Contraception

In June 2022, the U.S. Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, overturning Roe v. Wade and ending the federal constitutional right to abortion. While Dobbs is technically about abortion, its implications for contraception are direct and significant. As of mid-2025, 12 states have banned abortion outright, and 29 others have imposed severe restrictions (Anderson et al., 2025). In a notable concurring opinion, Justice Clarence Thomas explicitly argued that the same legal reasoning used to overturn Roe should be applied to reconsider other landmark cases — including Griswold v. Connecticut, the very case that established the right to contraception in 1965 (Weisman et al., 2025). No legal challenge to Griswold has yet succeeded, but the signal was clear.

The behavioral effects of Dobbs on contraceptive practice have already been measurable. A 2024 national survey found that 17% of reproductive-age people had changed their contraceptive practices in response to the decision — initiating contraception, switching to more effective methods, keeping emergency contraception on hand, or seeking permanent sterilization (Weisman et al., 2025). Rates of both tubal ligation and vasectomy among adults aged 18–30 increased significantly in the post-Dobbs period, a striking shift in a demographic not historically associated with sterilization (Weisman et al., 2025).

At the state level, 14 states and Washington, D.C. have moved to codify the right to contraception through legislation or constitutional amendments — six of them doing so specifically in response to Dobbs (Weisman et al., 2025). The federal Right to Contraception Act was introduced in Congress in 2022 but has not passed both chambers. Among states with abortion bans, only Florida currently has a codified right to contraception.

Mifepristone, the Comstock Act, and the Abortifacient Debate

Mifepristone is a medication used in combination with misoprostol for medication abortion — the method used by the majority of people seeking abortion in countries where it is legal, and considered very safe and effective when used before 10 weeks of pregnancy (Anderson et al., 2025). It is not a contraceptive. However, its legal status has become a flashpoint in the broader struggle over reproductive healthcare access, and students of reproductive health need to understand it.

In 2022, the Alliance for Hippocratic Medicine filed a federal lawsuit challenging the FDA’s approval of mifepristone and invoking the 1873 Comstock Act — which prohibits using postal carriers to transport abortion-related material — to restrict the drug’s distribution by mail. The Supreme Court ruled in June 2024 that the plaintiffs lacked legal standing to bring the case, meaning mifepristone remains available under current FDA policy (Weisman et al., 2025). However, future litigation using the same arguments remains a live threat.

Alongside challenges to mifepristone, anti-abortion groups have advanced the argument that several widely used contraceptive methods — specifically emergency contraception and IUDs — function as abortifacients by preventing implantation of a fertilized egg (Weisman et al., 2025). This claim is contested by mainstream medical science. The American College of Obstetricians and Gynecologists (ACOG) defines pregnancy as beginning at implantation — not fertilization — and states explicitly that none of the FDA-approved contraceptive methods interfere with an established pregnancy (American College of Obstetricians and Gynecologists [ACOG], 2025; Anderson et al., 2025). If courts were to accept the abortifacient framing, however, emergency contraception and IUDs could be removed from the list of methods covered at no cost under the Affordable Care Act — a significant material threat to access.

Insurance Coverage: History and Current Challenges

Understanding how contraceptive coverage policy developed helps clarify what is now at stake. Access to affordable contraception is not just a matter of legal rights — it is a matter of who can actually pay for it.

Contraceptive coverage policy in the United States has evolved in three waves (Weisman et al., 2025). The first wave began after Griswold, with states expanding Medicaid coverage for family planning services for low-income people. The second wave saw state legislatures passing contraceptive equity laws requiring private health plans to cover contraception on par with other prescription medications — by 2010, 29 states and D.C. had such laws, though most included religious exemptions and none applied to self-insured plans, which cover the majority of workers.

The third and most sweeping wave was the Affordable Care Act (ACA) of 2010 — the first federal law to require most private health insurance plans to cover all 18 FDA-approved contraceptive categories at zero out-of-pocket cost to the patient (Weisman et al., 2025). This was a landmark change for reproductive healthcare access: contraception was recognized as an essential component of women’s preventive care, equivalent to other evidence-based preventive services.

That coverage has since been steadily eroded through a series of legal challenges. In Burwell v. Hobby Lobby Stores, Inc. (2014), the Supreme Court ruled that “closely held” for-profit corporations could opt out of the contraceptive coverage requirement on religious liberty grounds. In Little Sisters of the Poor v. Pennsylvania (2020), the Court upheld rules allowing any employer with religious or moral objections to decline contraceptive coverage — without notifying the government or their employees (Weisman et al., 2025). Because there is no reporting requirement, it is unknown how many employers have exercised this exemption.

Despite the ACA mandate, a 2024 national survey found that 24% of privately insured people who used contraception in the previous 12 months paid at least some out-of-pocket costs (Weisman et al., 2025). The gap between the policy on paper and the reality on the ground is significant.

The second Trump administration has accelerated these pressures. Funding was withdrawn from Planned Parenthood and Title X, the federal program providing reproductive healthcare to low-income and uninsured people. The administration also froze funding for major global family planning programs — including those that provided contraceptive care to 47.6 million women and girls across 150 countries in 2024 (Anderson et al., 2025). The Mexico City Policy, which prohibits U.S. foreign aid from supporting organizations that provide or counsel about abortion, was reinstated and expanded. Evidence links the implementation of this policy to increased rates of unintended pregnancy, unsafe abortion, and maternal death in low-income countries (Anderson et al., 2025).

Digital Reproductive Health Tools and Data Privacy

Technology has become an increasingly significant part of how people access reproductive health information and manage contraception. Cycle-tracking apps, contraceptive decision-support tools, and pregnancy monitoring platforms — sometimes grouped under the term “FemTech” — have the potential to democratize access to high-quality health information, particularly for people who face barriers to in-person care (Callegari et al., 2026). Newer tools have been explicitly designed to serve marginalized communities, including people of color, LGBTQ+ individuals, and those with chronic medical conditions.

But the post-Dobbs legal landscape has introduced serious new risks for users of digital reproductive health tools. Unlike medical records held by healthcare systems, data in commercial apps is generally not protected by the Health Insurance Portability and Accountability Act (HIPAA). App data can be sold to third parties or subpoenaed by law enforcement. A high-profile case in Nebraska illustrated the stakes: police obtained a search warrant for private Facebook messages, which were then used to charge a mother and daughter for violating the state’s abortion law (Callegari et al., 2026). Similar risks apply to period-tracking apps, fertility trackers, and any digital tool that records information about reproductive health decisions or behaviors.

The behavioral effects of this concern are already measurable. Research found a significant decline in fertility and health app use in the weeks following the Dobbs ruling, with particularly notable drops among younger users — the demographic most likely to be reading this chapter (Callegari et al., 2026). Some users have begun entering false information to protect their privacy. Companies that have publicly committed not to share user data have seen increased downloads, while others have faced user attrition.

The Biden administration issued the HIPAA Reproductive Health Care Privacy Rule in 2024, which extended some protections to reproductive health information held by healthcare providers and limited the circumstances under which it could be disclosed. That rule is currently being challenged in federal court by attorneys general from 15 states (Callegari et al., 2026). Some states have passed shield laws offering parallel protections.

What does this mean practically? If you use a period-tracking app, a contraceptive decision tool, or any app that collects data about your reproductive health, it is worth reviewing its data privacy policy — specifically, whether it shares data with third parties, how long it retains data, and whether it offers a way to permanently delete your information. This is not a reason to avoid these tools, many of which are genuinely useful. It is a reason to be an informed user (Callegari et al., 2026).

Innovations on the Horizon

Despite the headwinds facing contraceptive access in the United States, the science of contraception is advancing in genuinely exciting directions. Research that has stalled for decades is gaining renewed momentum, and several innovations currently in development could meaningfully expand contraceptive options for diverse populations.

Non-hormonal female contraception represents one of the most eagerly anticipated areas. Ovaprene, an investigational hormone-free monthly intravaginal ring developed by Dare Bioscience, uses a physical polymer barrier combined with ferrous gluconate to immobilize sperm without introducing systemic hormones. Phase 3 clinical trials began in 2023 (Anderson et al., 2025). For people who cannot or prefer not to use hormonal methods, a non-hormonal, non-permanent option would be a significant development.

Multipurpose prevention technologies (MPTs) aim to address more than one reproductive health concern simultaneously. The OneRing, being developed by the Oak Crest Institute of Science, is a monthly vaginal ring designed to protect against both STIs (including HIV) and unintended pregnancy by combining an anti-HIV agent with a sperm motility inhibitor (Anderson et al., 2025). Phase 1 clinical trials are planned for the United States and sub-Saharan Africa. For populations at high risk for both HIV and unintended pregnancy — particularly in lower-income countries — this kind of combined protection could be transformative.

Finally, immunocontraception — the development of contraceptive vaccines targeting sperm antigens, hormones, or fertilization proteins — has been in exploratory research for decades. While not yet in advanced trials, this area holds long-term promise for both male and female vaccine-based contraception (Anderson et al., 2025).

Who shapes the contraceptive research agenda matters. Historically, that agenda has been driven by concerns about population control rather than individual autonomy — with predictable consequences for who got studied and who got harmed. The emerging emphasis on options for men and gender-diverse people, on non-hormonal methods, and on tools designed specifically for underserved communities reflects a more equitable vision of what reproductive science can be.

Conclusion

The history and present reality of contraception in the United States refuse to be neatly resolved. On one side: extraordinary innovation, expanding autonomy, and the real possibility of a more equitable contraceptive future. On the other: a history of coercion and forced sterilization that has never been fully reckoned with, a contemporary political landscape that is actively contracting reproductive rights, and persistent inequities in who can access care and who bears the costs of inadequate care.

What this chapter has tried to do is hold both of those realities together, because both are true. The birth control pill was revolutionary. It also emerged from a movement entangled with eugenics. LARCs are among the most effective contraceptive options available. They have also been used coercively against low-income women of color. Digital tools can democratize health information. They can also expose vulnerable people to legal risk. None of these technologies are neutral; all of them exist within social and political contexts that shape who benefits and who is harmed.

The goal, then, is not just scientific literacy about how contraceptive methods work — though that matters. It is the development of a critical lens: an ability to ask who has access, who has been harmed, whose voices have been heard in the design of contraceptive services, and what structural changes would make reproductive healthcare genuinely just. That is work for healthcare providers and researchers, yes, but it is also work for engaged citizens. And that includes you.

Reflection Questions

  1. This chapter discusses how different societies and cultures throughout history have approached contraception. How do you think cultural attitudes and beliefs influence contraceptive use and access today? Can you think of any examples from your own experiences or observations?
  2. The development of hormonal contraceptives, particularly the birth control pill, had a significant impact on society. How do you think the availability of reliable contraception has influenced gender roles, relationships, and women’s rights over the past several decades?
  3. Importantly, we discussed the dark history of forced sterilization in the United States, particularly targeting marginalized communities. How might this history impact trust in healthcare systems and contraceptive counseling for certain populations today? What steps could healthcare providers take to address this?
  4. Consider the various types of contraceptive methods discussed in the chapter. What factors do you think individuals should consider when choosing a contraceptive method? How might these considerations vary based on a person’s circumstances, identity, or stage of life?
  5. We highlight disparities in contraceptive access and use among different demographic groups. What are some potential strategies or policy changes that could help reduce these disparities and ensure more equitable access to contraceptive care?
  6. The Dobbs v. Jackson decision has had measurable effects on contraceptive behavior, including changes in app use and increases in sterilization requests. How do you think the political and legal environment shapes the personal health decisions people make? What responsibilities do healthcare providers, researchers, and policymakers have in this context?
  7. Digital tools like period-tracking apps and contraceptive decision aids can expand access to reproductive health information. What data privacy concerns should users be aware of? How should the design and implementation of these tools change in the current legal landscape?

Licenses & Attributions

Edelman, A. (2026). How to use emergency contraception effectively. Ted-Ed. https://www.youtube.com/watch?v=P5pmMe3EarI. License: All Rights Reserved. License Terms: Standard YouTube license.

Hill, S. E. (2019, December 2). The surprising link between women’s brains and the birth control pill. TEDxVienna. https://www.youtube.com/watch?v=RdwLAyWHBVs. License: All Rights Reserved. License Terms: Standard YouTube license.

PBS. (2022, September 19). The origins of eugenics in America [Video]. YouTube. https://www.youtube.com/watch?v=Qsg5IwYRw9A.

Vlog Brothers (2017, July 21). On condom failure. [Video]. https://www.youtube.com/watch?v=Z4dO_K_DufQ. License: Published under  Creative Commons Attribution 3.0 license directly on YouTube.

References

American College of Obstetricians and Gynecologists. (2025). Birth control. [FAQ].https://www.acog.org/womens-health/faqs/birth-control

Amy, J. J., & Rowlands, S. (2018). Legalised non-consensual sterilisation – eugenics put into practice before 1945, and the aftermath. Part 1: USA, Japan, Canada and Mexico. The European Journal of Contraception & Reproductive Health Care, 23(2), 121–129. http://eprints.bournemouth.ac.uk/30553/3/Forced%20sterilisation-Part%201%20Final.pdf

Anderson, D. J., Bearak, J. M., Grimstad, F. W., Palanee-Phillips, T., & van der Straten, A. (2025). Biomedical innovations in contraception: Gaps, obstacles, and solutions for sexual and reproductive health. The Lancet, 406, 2119–2132.

Asbury, B. D. (2015). Backdoor to eugenics – the risks of prenatal diagnosis for poor, Black women. Duke Journal of Gender Law & Policy, 23, 1. https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1300&context=djglp

Bailey, M. J. (2010). “Momma’s got the pill”: How Anthony Comstock and Griswold v. Connecticut shaped US childbearing. American Economic Review, 100(1), 98–129.

Bania, J., Wrona, J., Fudali, K., Stęga, F., Rębisz, P. F., & Murawski, M. (2025). Male hormonal contraception – current stage of knowledge. Journal of Clinical Medicine, 14, 2188. https://doi.org/10.3390/jcm14072188

Bilger, B. (1998). The secret garden. Sciences, 38(1), 38–43. https://libproxy.pcc.edu/login?url=https://www.proquest.com/scholarly-journals/secret-garden/docview/212676114/se-2?accountid=8042

Black, K. I., Vromman, M., & French, R. S. (2025). Common myths and misconceptions surrounding hormonal contraception. Best Practice & Research Clinical Obstetrics & Gynaecology, 98, 102573. https://doi.org/10.1016/j.bpobgyn.2024.102573

Blakemore, E. (2016). The little-known history of the forced sterilization of Native American women. JSTOR Daily. https://daily.jstor.org/the-little-known-history-of-the-forced-sterilization-of-native-american-women/

Bonnington, A., Dianat, S., Kerns, J., Hastings, J., Hawkins, M., De Haan, G., & Obedin-Maliver, J. (2020). Society of Family Planning clinical recommendations: Contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. Contraception, 102(2), 70–82. https://doi.org/10.1016/j.contraception.2020.04.001

Buttar, A., & Seward, S. (2009). Enovid: The first hormonal birth control pill. Embryo Project Encyclopedia. http://embryo.asu.edu/handle/10776/1956

Callegari, L. S., Mosley, E. A., Borrero, S., Birru Talabi, M., Kazmerski, T. M., Donley, G., & Krishnamurti, T. (2026). Implementing digital sexual and reproductive health tools: Challenges and recommendations post-Dobbs. Contraception, 157, 110969. https://doi.org/10.1016/j.contraception.2025.110969

Centers for Disease Control & Prevention. (2025). Contraception. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. https://www.cdc.gov/reproductivehealth/contraception/index.htm

Centers for Disease Control & Prevention (August, 2024).U.S. Selected Practice Recommendations for Contraceptive Use, 2024. https://www.cdc.gov/mmwr/volumes/73/rr/rr7303a1.htm#intrauterinecontraception

Cipres, D., Seidman, D., Cloniger, C., Nova, C., O’Shea, A., & Obedin-Maliver, J. (2017). Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco. Contraception, 95(2), 186–189.

Cooper, D. B., & Mahdy, H. (2020). Oral contraceptive pills. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430882/

Copen, C. E. (2017). Condom use during sexual intercourse among women and men aged 15–44 in the United States: 2011–2015 National Survey of Family Growth. National Health Statistics Reports, (105), 1–18. https://www.cdc.gov/nchs/data/nhsr/nhsr105.pdf

Daniels, K., & Abma, J. C. (2018). Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, no. 327. https://www.cdc.gov/nchs/data/databriefs/db327-h.pdf

de Wit, A. E., Booij, S. H., Giltay, E. J., Joffe, H., Schoevers, R. A., & Oldehinkel, A. J. (2020). Association of use of oral contraceptives with depressive symptoms among adolescents and young women. JAMA Psychiatry, 77(1), 52–59. https://doi.org/10.1001/jamapsychiatry.2019.2838

Durante, J. C., Sims, J., Jarin, J., Gold, M. A., Messiah, S. E., & Francis, J. K. R. (2023). Long-acting reversible contraception for adolescents: A review of practices to support better communication, counseling, and adherence. Adolescent Health, Medicine and Therapeutics, 14, 97–114. https://doi.org/10.2147/AHMT.S374268

Guttmacher Institute. (2021). Contraceptive use in the United States by demographics [Fact Sheet]. https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states

Guttmacher Institute. (2024, May). Publicly supported family planning services in the United States. guttmacher.org

Hill, S. E. (2020). Feel like a different person on the pill? Here’s how it affects your mood. Ideas.TED. https://ideas.ted.com/how-the-birth-control-pill-affects-your-mood/

Horner-Johnson, W., Akobirshoev, I., Amutah-Onukagha, N. N., Slaughter-Acey, J. C., & Mitra, M. (2021). Preconception health risks among US women: Disparities at the intersection of disability and race or ethnicity. Women’s Health Issues, 31(1), 65–74.

Jackson, A. V., Wang, L. F., & Morse, J. (2017). Racial and ethnic differences in contraception use and obstetric outcomes: A review. Seminars in Perinatology, 41(5), 273–277.

Khan, F., Mukhtar, S., Dickinson, I. K., & Sriprasad, S. (2013). The story of the condom. Journal of the Urological Society of India, 29(1), 12–15. https://doi.org/10.4103/0970-1591.109976

Krase, K. (2014). History of forced sterilization and current U.S. abuses. Our Bodies Ourselves. https://www.ourbodiesourselves.org/book-excerpts/health-article/forced-sterilization/

Lehmiller, J. J. (2019). The psychology of human sexuality (2nd ed.). John Wiley & Sons.

Lewis, C. A., Kimmig, A. C. S., Zsido, R. G., Jank, A., Derntl, B., & Sacher, J. (2019). Effects of hormonal contraceptives on mood: A focus on emotion recognition and reactivity, reward processing, and stress response. Current Psychiatry Reports, 21(11), 115.

Manian, M. (2020). Immigration detention and coerced sterilization: History tragically repeats itself. ACLU News & Commentary. https://www.aclu.org/news/immigrants-rights/immigration-detention-and-coerced-sterilization-history-tragically-repeats-itself/

Nunez-Eddy, C., & Malladi, L. (2016; 2018). Margaret Higgins Sanger (1879–1966). Embryo Project Encyclopedia. http://embryo.asu.edu/handle/10776/11365

Pahnke, R., Mau-Moeller, A., Junge, M., Wendt, J., Weymar, M., Hamm, A. O., & Lischke, A. (2019). Oral contraceptives impair complex emotion recognition in healthy women. Frontiers in Neuroscience, 12, 1041.

Planned Parenthood. (2016). Statement about Margaret Sanger and Planned Parenthood’s mission. https://www.plannedparenthood.org/planned-parenthood-north-central-states/about-ppncs/media-relations/statement-about-margaret-sanger-and-planned-parenthoods-mission

Planned Parenthood. (2021). Birth control. https://www.plannedparenthood.org/learn/birth-control

Rocca, C. H., & Harper, C. C. (2012). Do racial and ethnic differences in contraceptive attitudes and knowledge explain disparities in method use? Perspectives on Sexual and Reproductive Health, 44(3), 150–158.

Stern, A. M. (2005). Sterilized in the name of public health: Race, immigration, and reproductive control in modern California. American Journal of Public Health, 95(7), 1128–1138. https://ajph.aphapublications.org/doi/pdfplus/10.2105/AJPH.2004.041608

Tye, M. (2020). Sexuality and our diversity: Integrating culture with the biopsychosocial. Flatworld.

Weisman, C. S., Velott, D., Zheng, A., Horvath, S., Leslie, D., & Chuang, C. H. (2025). Contraception coverage policy in the United States: History and current challenges. Women’s Health Issues, 35(3), 151–158. https://doi.org/10.1016/j.whi.2025.03.002

Wright, K. Q. (2020). Contraceptive selection and practice: Associations with self-identified race and socioeconomic disadvantage. Social Science & Medicine, 266, 113366.

 

definition

License

Icon for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Introduction to Human Sexuality: A Two-Part Introduction to the Psychology of Human Sexuality Copyright © 2026 by Ericka Goerling, PhD and Emerson Wolfe, MS is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, except where otherwise noted.

Share This Book